Immunogenicity of hepatitis A-inactivated vaccine administered to seronegative infants, and serological follow-up 12 months after second dose

Annalisa De Silvestri, Francesca Zara, Virginio Terulla, Roberto Brerra, Silvana Zucca, Cesare Belloni

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Aim: To evaluate a) the safety and immunogenicity of anti-HAV-inactivated vaccine administered during the first year of life to anti-HAV seronegative babies, and b) the antibody persistence in a low/intermediate endemic area. Methods: After having obtained informed written consent from mothers, 92 babies were vaccinated at 4 and 10 mo of age. All babies were seronegative at birth and did not present HAV-RNA shedding in three serial stool samples taken at 1, 2 and 3 mo of age. Results: No general side effects (fever > 38°C) were observed. After the first dose of vaccine, 70/82 (85.4%) babies developed anti-HAV > 10 mIU/ml and 36/82 (43.9%) > 20 mIU/ml. After the second dose of vaccine, all babies developed a titre > 20 mIU/ml, and GMT was 877 mIU/ml. After 1 y of follow-up, the decreasing rate was similar to that reported for adult populations. Furthermore, three babies doubled the titre observed 1 mo after the second dose, indicating the possible spread of HAV even in a low/intermediate endemic area. Conclusion: Anti-HAV vaccine is safe, immunogenic and able to induce immune memory, and can be integrated into the routine infant immunization schedule during the first year of life.

Original languageEnglish
Pages (from-to)1582-1585
Number of pages4
JournalActa Paediatrica, International Journal of Paediatrics
Volume95
Issue number12
DOIs
Publication statusPublished - Dec 1 2006

Fingerprint

Hepatitis A Vaccines
Hepatitis A Antibodies
Inactivated Vaccines
Vaccines
Immunization Schedule
Informed Consent
Fever
Mothers
Parturition
RNA
Safety
Antibodies
Population

Keywords

  • Anti-HAV vaccine
  • Immunization
  • Infants

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Immunogenicity of hepatitis A-inactivated vaccine administered to seronegative infants, and serological follow-up 12 months after second dose. / De Silvestri, Annalisa; Zara, Francesca; Terulla, Virginio; Brerra, Roberto; Zucca, Silvana; Belloni, Cesare.

In: Acta Paediatrica, International Journal of Paediatrics, Vol. 95, No. 12, 01.12.2006, p. 1582-1585.

Research output: Contribution to journalArticle

@article{ec9988709821447881576450c500081e,
title = "Immunogenicity of hepatitis A-inactivated vaccine administered to seronegative infants, and serological follow-up 12 months after second dose",
abstract = "Aim: To evaluate a) the safety and immunogenicity of anti-HAV-inactivated vaccine administered during the first year of life to anti-HAV seronegative babies, and b) the antibody persistence in a low/intermediate endemic area. Methods: After having obtained informed written consent from mothers, 92 babies were vaccinated at 4 and 10 mo of age. All babies were seronegative at birth and did not present HAV-RNA shedding in three serial stool samples taken at 1, 2 and 3 mo of age. Results: No general side effects (fever > 38°C) were observed. After the first dose of vaccine, 70/82 (85.4{\%}) babies developed anti-HAV > 10 mIU/ml and 36/82 (43.9{\%}) > 20 mIU/ml. After the second dose of vaccine, all babies developed a titre > 20 mIU/ml, and GMT was 877 mIU/ml. After 1 y of follow-up, the decreasing rate was similar to that reported for adult populations. Furthermore, three babies doubled the titre observed 1 mo after the second dose, indicating the possible spread of HAV even in a low/intermediate endemic area. Conclusion: Anti-HAV vaccine is safe, immunogenic and able to induce immune memory, and can be integrated into the routine infant immunization schedule during the first year of life.",
keywords = "Anti-HAV vaccine, Immunization, Infants",
author = "{De Silvestri}, Annalisa and Francesca Zara and Virginio Terulla and Roberto Brerra and Silvana Zucca and Cesare Belloni",
year = "2006",
month = "12",
day = "1",
doi = "10.1080/08035250600615119",
language = "English",
volume = "95",
pages = "1582--1585",
journal = "Acta Paediatrica, International Journal of Paediatrics",
issn = "0803-5253",
publisher = "Wiley-Blackwell",
number = "12",

}

TY - JOUR

T1 - Immunogenicity of hepatitis A-inactivated vaccine administered to seronegative infants, and serological follow-up 12 months after second dose

AU - De Silvestri, Annalisa

AU - Zara, Francesca

AU - Terulla, Virginio

AU - Brerra, Roberto

AU - Zucca, Silvana

AU - Belloni, Cesare

PY - 2006/12/1

Y1 - 2006/12/1

N2 - Aim: To evaluate a) the safety and immunogenicity of anti-HAV-inactivated vaccine administered during the first year of life to anti-HAV seronegative babies, and b) the antibody persistence in a low/intermediate endemic area. Methods: After having obtained informed written consent from mothers, 92 babies were vaccinated at 4 and 10 mo of age. All babies were seronegative at birth and did not present HAV-RNA shedding in three serial stool samples taken at 1, 2 and 3 mo of age. Results: No general side effects (fever > 38°C) were observed. After the first dose of vaccine, 70/82 (85.4%) babies developed anti-HAV > 10 mIU/ml and 36/82 (43.9%) > 20 mIU/ml. After the second dose of vaccine, all babies developed a titre > 20 mIU/ml, and GMT was 877 mIU/ml. After 1 y of follow-up, the decreasing rate was similar to that reported for adult populations. Furthermore, three babies doubled the titre observed 1 mo after the second dose, indicating the possible spread of HAV even in a low/intermediate endemic area. Conclusion: Anti-HAV vaccine is safe, immunogenic and able to induce immune memory, and can be integrated into the routine infant immunization schedule during the first year of life.

AB - Aim: To evaluate a) the safety and immunogenicity of anti-HAV-inactivated vaccine administered during the first year of life to anti-HAV seronegative babies, and b) the antibody persistence in a low/intermediate endemic area. Methods: After having obtained informed written consent from mothers, 92 babies were vaccinated at 4 and 10 mo of age. All babies were seronegative at birth and did not present HAV-RNA shedding in three serial stool samples taken at 1, 2 and 3 mo of age. Results: No general side effects (fever > 38°C) were observed. After the first dose of vaccine, 70/82 (85.4%) babies developed anti-HAV > 10 mIU/ml and 36/82 (43.9%) > 20 mIU/ml. After the second dose of vaccine, all babies developed a titre > 20 mIU/ml, and GMT was 877 mIU/ml. After 1 y of follow-up, the decreasing rate was similar to that reported for adult populations. Furthermore, three babies doubled the titre observed 1 mo after the second dose, indicating the possible spread of HAV even in a low/intermediate endemic area. Conclusion: Anti-HAV vaccine is safe, immunogenic and able to induce immune memory, and can be integrated into the routine infant immunization schedule during the first year of life.

KW - Anti-HAV vaccine

KW - Immunization

KW - Infants

UR - http://www.scopus.com/inward/record.url?scp=33845260084&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845260084&partnerID=8YFLogxK

U2 - 10.1080/08035250600615119

DO - 10.1080/08035250600615119

M3 - Article

C2 - 17129966

AN - SCOPUS:33845260084

VL - 95

SP - 1582

EP - 1585

JO - Acta Paediatrica, International Journal of Paediatrics

JF - Acta Paediatrica, International Journal of Paediatrics

SN - 0803-5253

IS - 12

ER -